All patients
Age < 65y (younger) Age > 65y Gender, female Gender, male metastasis (bone) PD-L1 < 1% PD-L1 > 1% previous nephrectomy (no) previous nephrectomy (yes) Risk favorable (IMDC) Risk intermediate (IMDC) Risk poor (IMDC)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced RCC (mRCC) - 1st line (L1), nivolumab plus cabozantinib vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 9ER, 2021 0.60 [0.40; 0.89]
0.60 [0.40 ; 0.89 ] CheckMate 9ER, 2021 1 0% 651 NA not evaluable deaths (OS) (extension)detailed results CheckMate 9ER, 2021 0.70 [0.55; 0.90]
0.70 [0.55 ; 0.90 ] CheckMate 9ER, 2021 1 0% 651 NA not evaluable PFS (extension)detailed results CheckMate 9ER, 2021 0.56 [0.46; 0.68]
0.56 [0.46 ; 0.68 ] CheckMate 9ER, 2021 1 0% 651 NA not evaluable progression or deaths (PFS)detailed results CheckMate 9ER, 2021 0.51 [0.41; 0.64]
0.51 [0.41 ; 0.64 ] CheckMate 9ER, 2021 1 0% 651 NA not evaluable objective responses (ORR)detailed results CheckMate 9ER, 2021 3.38 [2.44; 4.69]
3.38 [2.44 ; 4.69 ] CheckMate 9ER, 2021 1 0% 651 NA not evaluable objective responses (ORR) (extension)detailed results CheckMate 9ER, 2021 3.18 [2.30; 4.40]
3.18 [2.30 ; 4.40 ] CheckMate 9ER, 2021 1 0% 651 NA not evaluable TRAE (any grade)detailed results CheckMate 9ER, 2021 2.14 [1.02; 4.46]
2.14 [1.02 ; 4.46 ] CheckMate 9ER, 2021 1 0% 651 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 9ER, 2021 0.51 [0.05; 5.61]
0.51 [0.05 ; 5.61 ] CheckMate 9ER, 2021 1 0% 651 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 9ER, 2021 1.84 [1.13; 3.00]
1.84 [1.13 ; 3.00 ] CheckMate 9ER, 2021 1 0% 651 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-06 15:08 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 79,178,152
- treatments: 842